The Longitudinal Kinetics of AAV5 Vector Integration Profiles in Mice

被引：0
|
作者：
Ismail, Ashrafali Mohamed [1 ]
Witt, Evan [1 ]
Bouwman, Taren [1 ]
Clark, Wyatt [1 ]
Yates, Bridget [1 ]
Franco, Matteo [2 ,3 ]
Fong, Sylvia [1 ]
机构：
[1] BioMarin Pharmaceut Inc, Novato, CA USA
[2] ProtaGene CGT GmbH, Heidelberg, Germany
[3] ProtaGene US Inc, Burlington, MA USA
来源：
MOLECULAR THERAPY | 2023年 / 31卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
65
引用
收藏
页码：35 / 35
页数：1
相关论文
共 50 条
  • [31] Non-canonical amino acid incorporation into AAV5 capsid enhances lung transduction in mice
    Chang, Hao
    Du, Ailing
    Jiang, Jun
    Ren, Lingzhi
    Liu, Nan
    Zhou, Xuntao
    Liang, Jialing
    Gao, Guangping
    Wang, Dan
    MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT, 2023, 31
  • [32] Identification and Mutagenesis of the AAV5 Sialic Acid Binding Region
    Afione, Sandra
    DiMattia, Michael A.
    Halder, Sujata
    Di Pasquale, Giovanni
    Agbandje-McKenna, Mavis
    Chiorini, John
    MOLECULAR THERAPY, 2015, 23 : S39 - S39
  • [33] Trophism of AAV2 and AAV5 vectors in the non-human primate retina
    Lotery, AJ
    Derksen, TA
    Russell, SR
    Mullins, RF
    Yang, GS
    Kopp, KK
    Eastman, CG
    Stone, EM
    Davidson, BL
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2002, 43 : U1308 - U1308
  • [34] Comparison of gene expression after intraperitoneal delivery of AAV2 or AAV5 in utero
    Lipshutz, GS
    Titre, D
    Brindle, M
    Bisconte, AR
    Contag, CH
    Gaensler, KML
    MOLECULAR THERAPY, 2003, 8 (01) : 90 - 98
  • [35] Directed Evolution of AAV1, AAV5 and AAV9 Variants for Efficient Gene Delivery to Eye
    Pendse, Nachiket
    Magdaleno, Eduardo
    Luna, Fabio
    Ge, Tan
    Hintzen, Steph
    Hill, Jake
    Mcelroy, Cameron
    Chen, Jayson
    Tam, Lawrence
    Hudry, Eloise
    Booler, Helen
    Stoner, Kirsten
    Penraat, Kelley
    Hedgeland, Mark
    Babaria, Shraddha
    Walker, John
    Ellis, Scott
    Ozsolak, Fatih
    MOLECULAR THERAPY, 2024, 32 (04) : 479 - 479
  • [36] Transduction of murine cerebellar neurons with recombinant FIV and AAV5 vectors
    Alisky, JM
    Hughes, SM
    Sauter, SL
    Jolly, D
    Dubensky, TW
    Staber, PD
    Chiorini, JA
    Davidson, BL
    NEUROREPORT, 2000, 11 (12) : 2669 - 2673
  • [37] Nanobodies inserted into different surface loops retarget AAV5 and AAV9 to specific cells
    Schaefer, W.
    Richter, N.
    Jargalsaikhan, S.
    Haag, F.
    Braren, I.
    Thirion, C.
    Adriouch, S.
    Koch-Nolte, F.
    Mann, A. M.
    HUMAN GENE THERAPY, 2024, 35 (3-4) : A68 - A68
  • [38] A study of the seroprevalence of adenovirus-associated virus vector-serotype AAV5 neutralizing activity and antibodies in patients with haemophilia A
    Stanford, Sophia
    Oyesiku, Lara
    Pink, Ruth
    Creagh, Desmond
    Clark, Amanda
    Jane, Needham
    Rangarajan, Savita
    HAEMOPHILIA, 2016, 22 : 46 - 46
  • [39] Testing cone targeting with AAV5 and the GRK1 promoter in mice for future CRISPR-based applications
    Rhodes, Ellen
    Salman, Ahmed
    McClements, Michelle E.
    MacLaren, Robert E.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [40] The Human Rhodopsin Kinase Promoter in an AAV5 Vector Confers Rod- and Cone-Specific Expression in the Primate Retina
    Boye, Shannon E.
    Alexander, John J.
    Boye, Sanford L.
    Witherspoon, Clark D.
    Sandefer, Kristen J.
    Conlon, Thomas J.
    Erger, Kirsten
    Sun, Jingfen
    Ryals, Renee
    Chiodo, Vince A.
    Clark, Mark E.
    Girkin, Christopher A.
    Hauswirth, William W.
    Gamlin, Paul D.
    HUMAN GENE THERAPY, 2012, 23 (10) : 1101 - 1115
12345